RFID meeting
This article was originally published in The Tan Sheet
Executive Summary
A public workshop Feb. 8-9 will allow FDA's Counterfeit Drug Task Force to collect stakeholder input on identifying "incentives for widespread adoption of radio frequency identification (RFID), as well as obstacles," according to a Federal Register announcement Jan. 11. Specifically, the agency seeks input on how to address the likelihood that widespread RFID technology will not be in operation by the current deadline for implementation under the Prescription Drug Marketing Act's pedigree requirements. Comments will "guide the agency's decision whether to continue the delayed effective date, let the regulatory provisions go into effect, or take other steps," the announcement states. In 2004, FDA cited implementation of electronic track and trace capability by 2007 as a priority. However, "it appears that the goals described previously may not be met," FDA states...
You may also be interested in...
No Disguising Need For Enforcement, Education To Curb Counterfeiting
Consumer education programs and increased law enforcement efforts are needed to curtail the counterfeiting of drugs and personal care products, according to a lawyer with a prominent intellectual property law firm
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.